Patents by Inventor Ekambar Kandimalla

Ekambar Kandimalla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220064649
    Abstract: Aspects of the invention relate to compositions of spherical nucleic acids (SNAs) composed of a liposome or lipoplex complex having an oligonucleotide shell with CpG oligonucleotides positioned on the exterior of the liposome or lipoplex. The invention also relates to methods of treating subjects and of inducing cytokine expression in a subject using the compositions described herein.
    Type: Application
    Filed: April 15, 2021
    Publication date: March 3, 2022
    Applicant: Exicure, Inc.
    Inventors: Bart Anderson, Subbarao Nallagatla, Richard Kang, Ekambar Kandimalla
  • Publication number: 20210002640
    Abstract: Compositions related to spherical nucleic acids (SNAs) and structures with antisense oligonucleotides and methods of treatment of diseases and disorders are disclosed herein.
    Type: Application
    Filed: February 28, 2019
    Publication date: January 7, 2021
    Applicant: Exicure, Inc.
    Inventors: Richard Kang, Subbarao Nallagatla, Bart Anderson, Ekambar Kandimalla, Michael Mutolo
  • Publication number: 20200255837
    Abstract: Aspects of the invention relate to compositions of spherical nucleic acids (SNAs) composed of a liposome or lipoplex complex having an oligonucleotide shell with CpG oligonucleotides positioned on the exterior of the liposome or lipoplex. The invention also relates to methods of treating subjects and of inducing cytokine expression in a subject using the compositions described herein.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 13, 2020
    Applicant: Exicure, Inc.
    Inventors: Bart Anderson, Subbarao Nallagatla, Richard Kang, Ekambar Kandimalla
  • Publication number: 20200248183
    Abstract: Aspects of the invention relate to immunostimulatory spherical nucleic acids (IS-SNA) for the treatment of a disorder, such as cancer. The IS-SNA may be administered together with a checkpoint inhibitor.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 6, 2020
    Inventors: Subbarao Nallagatla, Bart ANDERSON, Ekambar KANDIMALLA
  • Publication number: 20200188521
    Abstract: Spherical nucleic acids (SNA) carrying self-aggregating oligonucleotides are described herein. Compositions of the SNA include discrete nanostructures that are not aggregated. Related methods are also described.
    Type: Application
    Filed: April 27, 2018
    Publication date: June 18, 2020
    Applicant: Exicure, Inc.
    Inventors: Richard Kang, Subbarao Nallagatla, Bart Anderson, Ekambar Kandimalla
  • Publication number: 20190225968
    Abstract: Aspects of the invention relate to compositions of spherical nucleic acids (SNAs) composed of a liposome or lipoplex complex having an oligonucleotide shell with CpG oligonucleotides positioned on the exterior of the liposome or lipoplex. The invention also relates to methods of treating subjects and of inducing cytokine expression in a subject using the compositions described herein.
    Type: Application
    Filed: May 5, 2017
    Publication date: July 25, 2019
    Applicant: Exicure, Inc.
    Inventors: Bart Anderson, Subbarao Nallagatla, Richard Kang, Ekambar Kandimalla
  • Publication number: 20160201060
    Abstract: The invention provides immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Application
    Filed: January 8, 2016
    Publication date: July 14, 2016
    Inventors: Ekambar Kandimalla, Daqing Wang, Dong Yu, Ireneusz Nowak, Sudhir Agrawal
  • Patent number: 8987221
    Abstract: The invention provides the use of immune regulatory oligonucleotides (IRO) as antagonist of TLRs and potentiators of anti-inflammatory agents that inhibit TNF for the prevention and treatment of inflammatory and autoimmune diseases.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: March 24, 2015
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Fu-Gang Zhu, Ekambar Kandimalla, Sudhir Agrawal
  • Publication number: 20150044196
    Abstract: The inventors have examined the means for providing more efficacious miRNA blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of miRNA blocking molecules. These features include the presence of multiple 3? ends and a linker at the 5? ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology.
    Type: Application
    Filed: September 24, 2014
    Publication date: February 12, 2015
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Mallikarjuna Putta, Tao Lan, Ireneusz Nowak, Nicola LaMonica, Weiwen Jiang, Michael Reardon
  • Patent number: 8877722
    Abstract: The inventors have examined the means for providing more efficacious miRNA blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of miRNA blocking molecules. These features include the presence of multiple 3? ends and a linker at the 5? ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: November 4, 2014
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Mallikarjuna Putta, Ireneusz Nowak, Nicola LaMonica, Weiwen Jiang, Michael Reardon, Tao Lan
  • Patent number: 8853177
    Abstract: The invention provides the use of TLR inhibitors or a pharmaceutically acceptable derivative thereof, optionally in combination with one or more lipid lowering composition, cholesterol lowering composition, diuretics, non-steroidal anti-inflammatory compounds (NSAIDs), antibodies, antisense oligonucleotides, TLR agonists, TLR antagonists, peptides, proteins or gene therapy vectors or combinations thereof for the prevention or treatment of hypercholesterolemia and/or hyperlipidemia and/or diseases associated therewith.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: October 7, 2014
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Fu-Gang Zhu, Ekambar Kandimalla, Sudhir Agrawal
  • Patent number: 8853375
    Abstract: The invention relates to TLR9 antagonist compounds and their therapeutic or prophylactic use. The invention provides novel immune regulatory oligonucleotides and immunomers as antagonist of TLRs and methods of use thereof. These immune regulatory oligonucleotides have unique sequences that suppress, without completely ablating, TLR-mediated signaling in response to a TLR ligand or TLR signaling agonist. The methods may have use in the prevention and treatment of autoimmunity, inflammation, inflammatory bowel disease, lupus, allergy, asthma, infection, sepsis, cancer and immunodeficiency.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: October 7, 2014
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar Kandimalla, Lakshmi Bhagat, Mallikarjuna Putta, Daqing Wang, Sudhir Agrawal
  • Patent number: 8492358
    Abstract: TLR3 agonist compounds, compositions and methods are provided for stimulating the activity of TLR3. The compositions comprise oligonucleotide-based compounds that bind to and activate TLR3. The compositions may also comprise oligonucleotide-based compounds that bind to and activate TLR3 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for stimulation of TLR3 activity and for prevention or treatment of diseases wherein modulation of TLR3 activity would be beneficial are provided.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: July 23, 2013
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar Kandimalla, Tao Lan, Victoria Jane Philbin, Sudhir Agrawal
  • Publication number: 20130142778
    Abstract: The inventors have examined the means for providing more efficacious miRNA blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of miRNA blocking molecules. These features include the presence of multiple 3? ends and a linker at the 5? ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology.
    Type: Application
    Filed: March 25, 2011
    Publication date: June 6, 2013
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: SUDHIR AGRAWAL, EKAMBAR KANDIMALLA, MALLIKARJUNA PUTTA, Ireneusz Nowak, Nicola LaMonica, Weiwen Jiang, Michael Reardon, Tao Lan
  • Patent number: 8431544
    Abstract: The inventors have examined the means for providing more efficacious gene expression blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of gene expression blocking molecules. These features include the presence of multiple 3? ends and a linker at the 5? ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technologies.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: April 30, 2013
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Mallikarjuna Putta, Tao Lan, Lakshmi Bhagat, Daqing Wang, Dong Yu
  • Patent number: 8426375
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: April 23, 2013
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar Kandimalla, Daqing Wang, Yukui Li, Dong Yu, FuGang Zhu, Lakshmi Bhagat, Sudhir Agrawal
  • Patent number: 8420615
    Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
    Type: Grant
    Filed: September 23, 2009
    Date of Patent: April 16, 2013
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu
  • Patent number: 8399423
    Abstract: The invention provides the use of immune regulatory oligonucleotides (IRO) as antagonist of TLRs in the prevention and treatment of a disease caused by a pathogen, for example, a DNA or RNA virus.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: March 19, 2013
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar Kandimalla, Daqing Wang, Yukui Li, Dong Yu, FuGang Zhu, Lakshmi Bhagat, Sudhir Agrawal
  • Patent number: 8383598
    Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: February 26, 2013
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar Kandimalla, Daqing Wang, Yukui Li, Dong Yu, FuGang Zhu, Lakshmi Bhagat, Sudhir Agrawal
  • Publication number: 20120183530
    Abstract: The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
    Type: Application
    Filed: January 27, 2012
    Publication date: July 19, 2012
    Inventors: Ekambar Kandimalla, Tao Lan, Daqing Wang, Lakshmi Bhagat, Sudhir Agrawal